About Maxwell Biomedical

About company

Maxwell Biomedical develops wireless and battery-less medical device for the treatment of AFib. Atrial Fibrillation is the most common arrhythmia diagnosed in clinical practice, affecting over 33 Million individuals worldwide and is expected to more than double in the next 50 years as the population ages. The company focuses on searching for a new therapy along with continuous patient management to improve daily and long-term outcomes with the improved safety profiles for patients with Atrial Fibrillation are needed.